Feeds
3807 items (3807 unread) in 74 feeds
Acinar Cell Carcinoma
(40 unread)
Acinic Cell Carcinoma
(50 unread)
Adenoid Cystic Carcinoma
(96 unread)
Adrenal Gland Cancer
(350 unread)
Ampulla Of Vater
(53 unread)
Anal Cancer
(367 unread)
Angiosarcoma
(88 unread)
Appendix Cancer
(50 unread)
Bile Duct Cancer
(400 unread)
Brain and CNS
(353 unread)
Carcinoid
(144 unread)
Endocrine/Neuroendocrine
(453 unread)
Gall Bladder Cancer
(301 unread)
Hemangioendothelioma
(90 unread)
Hepatoblastoma
(50 unread)
Pancreas
(28 unread)
Phyllodes
(17 unread)
PMP and Mucinous Tumors
(22 unread)
Rhabdomyosarcoma
(212 unread)
Sarcoma
(643 unread)
Google - Cholangiocarcinoma (91 unread)
-
Brian 'Flip' Earley - Seymour Tribune
Posted: January 15th, 2022, 1:00am GMT
Brian 'Flip' Earley Seymour Tribune -
'He'll be missed by all': Shelton police officer remembered for dedication to family, city - Shelton Herald
Posted: January 14th, 2022, 9:18pm GMT
-
'He'll be missed by all': Shelton police officer remembered for dedication to family, city - Torrington Register Citizen
Posted: January 14th, 2022, 7:20pm GMT
'He'll be missed by all': Shelton police officer remembered for dedication to family, city Torrington Register Citizen -
Helsinn, the Braglia family pharma, sees some big changes in leadership as it unveils a new R&D strategy - Endpoints News
Posted: January 14th, 2022, 2:20pm GMT
-
Positive results for RedHill's novel coronavirus treatment - The Pharma Letter
Posted: January 14th, 2022, 12:29pm GMT
Positive results for RedHill's novel coronavirus treatment The Pharma Letter -
Mayo dad diagnosed with rare life-threatening cancer after a sharp pain in his side - RSVP Live
Posted: January 13th, 2022, 5:57pm GMT
-
County mayor proclaims February 'Cholangiocarcinoma Awareness Month' | Local News | williamsonherald.com - williamsonherald.com
Posted: January 13th, 2022, 5:36pm GMT
-
RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients - PRNewswire
Posted: January 13th, 2022, 1:35pm GMT
-
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes - Yahoo Finance
Posted: January 13th, 2022, 10:00am GMT
-
Ever awesome: Remembering Bill Gnade | Local News | sentinelsource.com - The Keene Sentinel
Posted: January 13th, 2022, 9:00am GMT
Ever awesome: Remembering Bill Gnade | Local News | sentinelsource.com The Keene Sentinel -
ASTRO provides new guidance on the use of external beam radiation therapy for primary liver cancers - News-Medical.Net
Posted: January 13th, 2022, 12:42am GMT
-
William H. Gnade Jr. | Obituaries | sentinelsource.com - The Keene Sentinel
Posted: January 11th, 2022, 3:00pm GMT
William H. Gnade Jr. | Obituaries | sentinelsource.com The Keene Sentinel -
BRIEF—Servier Pharmaceuticals sets out progress in oncology - The Pharma Letter
Posted: January 11th, 2022, 11:35am GMT
BRIEF—Servier Pharmaceuticals sets out progress in oncology The Pharma Letter -
TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones - Yahoo Finance
Posted: January 10th, 2022, 9:45am GMT
-
William Gnade Obituary (2022) - Hancock, NH - Monadnock Ledger-Transcript - Legacy.com
Posted: January 10th, 2022, 10:55pm GMT
-
More than $40,000 raised for YK firefighter with rare cancer - Cabin Radio
Posted: January 8th, 2022, 8:15pm GMT
-
Family of Irish dad battling rare form of cancer share heartfelt message after thousands raised - Irish Mirror
Posted: January 7th, 2022, 11:51am GMT
-
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates - The Mountaineer
Posted: January 6th, 2022, 12:15pm GMT
-
Latin America Liver Cancer Market Study, Competitive Strategies, Key Manufacturers, New Project Investment and Forecast 2024 – Industrial IT - Industrial IT
Posted: January 6th, 2022, 11:16am GMT
-
Basilea reports on portfolio progress made in 2021 - BioSpace
Posted: January 6th, 2022, 6:53am GMT
-
Basilea reports on portfolio progress made in 2021 - GlobeNewswire
Posted: January 6th, 2022, 4:15am GMT
Basilea reports on portfolio progress made in 2021 GlobeNewswire -
TCR2 Therapeutics: Trading Below Cash - Seeking Alpha
Posted: January 6th, 2022, 1:59am GMT
TCR2 Therapeutics: Trading Below Cash Seeking Alpha -
A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma - Avera Health
Posted: January 5th, 2022, 7:37pm GMT
-
Immunotherapy Approvals Propel the Future of GI Cancer Treatment - www.oncnursingnews.com/
Posted: January 5th, 2022, 5:06pm GMT
Immunotherapy Approvals Propel the Future of GI Cancer Treatment www.oncnursingnews.com/ -
Cell Papers Present Tool to Visualize Single-Cell Data, Chinese Pine Genome Assembly, Intrahepatic Cholangiocarcinoma Proteogenomic Analysis - GenomeWeb
Posted: January 5th, 2022, 3:04pm GMT
-
Lynparza Rejection Highlights 'Two-Tier' Funding Problem In UK - Pink Sheet
Posted: January 5th, 2022, 7:51am GMT
-
Sirnaomics starts 2022 with $64M Hong Kong IPO - BioWorld Online
Posted: January 4th, 2022, 8:16pm GMT
Sirnaomics starts 2022 with $64M Hong Kong IPO BioWorld Online -
Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis, Research Study With Kyowa Hakko Kirin Co Ltd, Bristol-Myers Squibb Company, Mylan NV (US) – Industrial IT - Industrial IT
Posted: January 4th, 2022, 4:22pm GMT
-
Relay Therapeutics Advances Trials of PI3Kα, FGFR2 Inhibitors - Precision Oncology News
Posted: January 4th, 2022, 3:43pm GMT
Relay Therapeutics Advances Trials of PI3Kα, FGFR2 Inhibitors Precision Oncology News -
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008 - BioSpace
Posted: January 4th, 2022, 12:25pm GMT
-
Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment - Seeking Alpha
Posted: January 4th, 2022, 11:30am GMT
-
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and ... - The Bakersfield Californian
Posted: January 4th, 2022, 10:30am GMT
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and ... The Bakersfield Californian -
Buying BridgeBio Pharma On The Drop After Phase 3 Amyloidosis Failure - Seeking Alpha
Posted: January 4th, 2022, 8:52am GMT
-
Obituary: Kenneth Fairfield Morse Sr. - Portland Press Herald - pressherald.com
Posted: January 4th, 2022, 4:01am GMT
Obituary: Kenneth Fairfield Morse Sr. - Portland Press Herald pressherald.com -
Case 3: Multidisciplinary Care in HCC Management - Targeted Oncology
Posted: January 3rd, 2022, 5:20pm GMT
Case 3: Multidisciplinary Care in HCC Management Targeted Oncology -
Kenneth Fairfield Morse Sr. - The Lincoln County News
Posted: January 3rd, 2022, 6:00am GMT
Kenneth Fairfield Morse Sr. The Lincoln County News -
John Coliano | Obituary | The Daily News of Newburyport - The Daily News of Newburyport
Posted: January 3rd, 2022, 6:00am GMT
John Coliano | Obituary | The Daily News of Newburyport The Daily News of Newburyport -
Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines - DocWire News
Posted: January 1st, 2022, 4:00am GMT
-
Is Incyte Corporation (INCY) Stock About to Get Hot Friday? - InvestorsObserver
Posted: December 31st, 2021, 2:54pm GMT
Is Incyte Corporation (INCY) Stock About to Get Hot Friday? InvestorsObserver -
Pancreatic And Bile Duct Cancer Drugs Market Size, Analysis, Forecast to 2029 | Key Players – 3-V Biosciences, 4P-Pharma SAS, 4SC AG, AB Science SA, AbbVie, AbGenomics International – Industrial IT - Industrial IT
Posted: December 30th, 2021, 5:16pm GMT
-
Is BridgeBio Pharma Stock a Buy on the Dip? - The Motley Fool
Posted: December 29th, 2021, 8:41am GMT
Is BridgeBio Pharma Stock a Buy on the Dip? The Motley Fool -
Is BridgeBio Pharma Stock a Buy on the Dip? - Nasdaq
Posted: December 29th, 2021, 8:41am GMT
-
Roundtable Discussion: Finn Breaks Down the Challenges With Multiple Treatment Options in HCC - Targeted Oncology
Posted: December 28th, 2021, 6:05pm GMT
-
Surufatinib Monotherapy Shows Moderate Efficacy in Biliary Tract Carcinoma - Targeted Oncology
Posted: December 23rd, 2021, 6:09pm GMT
-
In Brief This Week: SkylineDx, TTC Oncology, LianBio - Precision Oncology News
Posted: December 23rd, 2021, 12:37pm GMT
In Brief This Week: SkylineDx, TTC Oncology, LianBio Precision Oncology News -
New EU Filings :: Pink Sheet - Pink Sheet
Posted: December 22nd, 2021, 9:10am GMT
New EU Filings :: Pink Sheet Pink Sheet -
Minimal surgery for intrahepatic cholangiocarcinoma | HMER - Dove Medical Press
Posted: December 22nd, 2021, 5:40am GMT
Minimal surgery for intrahepatic cholangiocarcinoma | HMER Dove Medical Press -
Former Logan Mayor Tom Esposito dead at 69 | News | loganbanner.com - The Logan Banner
Posted: December 22nd, 2021, 3:00am GMT
Former Logan Mayor Tom Esposito dead at 69 | News | loganbanner.com The Logan Banner -
Cost yield of different treatment strategies against Clonorchis sinensis infection - Infectious Diseases of Poverty - Infectious Diseases of Poverty - BioMed Central
Posted: December 22nd, 2021, 11:40pm GMT
Cost yield of different treatment strategies against Clonorchis sinensis infection - Infectious Diseases of Poverty Infectious Diseases of Poverty - BioMed Central -
Volunteers Make Big Strides With Raising Awareness, Funding Research for the Cholangiocarcinoma Foundation - Curetoday.com
Posted: December 21st, 2021, 5:03pm GMT
-
A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma - Avera Health
Posted: December 21st, 2021, 4:16pm GMT
-
Anheart Therapeutics raises $61M in series B for precision oncology pipeline - BioWorld Online
Posted: December 21st, 2021, 3:00pm GMT
-
LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China - BioSpace
Posted: December 21st, 2021, 11:05am GMT
-
Tumor endothelial marker TEM7 is a prognostic biomarker | IJGM - Dove Medical Press
Posted: December 21st, 2021, 10:52am GMT
Tumor endothelial marker TEM7 is a prognostic biomarker | IJGM Dove Medical Press -
LianBio Announces Infigratinib Approved Under Special Named - GlobeNewswire
Posted: December 21st, 2021, 10:00am GMT
-
Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearr - Yahoo Fin
Posted: December 21st, 2021, 8:00am GMT
-
Specialty Drug Approvals: A Year of Firsts - Pharmacy Practice News
Posted: December 21st, 2021, 3:06am GMT
Specialty Drug Approvals: A Year of Firsts Pharmacy Practice News -
ctDNA May Predict Worse Metastatic Biliary Tract Cancer Prognosis - Medscape
Posted: December 20th, 2021, 7:19pm GMT
-
FDA Grants Orphan Drug Designation to Silmitasertib To Treat Medulloblastoma - Targeted Oncology
Posted: December 20th, 2021, 3:10pm GMT
-
Helsinn Group Licenses Truseltiq to Xediton Pharmaceuticals for Sale in Canada - Precision Oncology News
Posted: December 20th, 2021, 1:06pm GMT
Helsinn Group Licenses Truseltiq to Xediton Pharmaceuticals for Sale in Canada Precision Oncology News -
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada - Yahoo Finance
Posted: December 20th, 2021, 11:03am GMT
-
Kathleen Levin Obituary (2021) - Atlanta, GA - Atlanta Journal-Constitution - Legacy.com
Posted: December 20th, 2021, 1:55am GMT
-
The week in pharma: action, reaction and insight - week to December 17 - The Pharma Letter
Posted: December 19th, 2021, 9:44am GMT
The week in pharma: action, reaction and insight - week to December 17 The Pharma Letter -
Levin, Kathleen - Atlanta Journal Constitution
Posted: December 19th, 2021, 3:07am GMT
Levin, Kathleen Atlanta Journal Constitution -
BRIEF—Genfit takes punt on cholangiocarcinoma candidate - The Pharma Letter
Posted: December 17th, 2021, 7:42pm GMT
BRIEF—Genfit takes punt on cholangiocarcinoma candidate The Pharma Letter -
Sector Update: Health Care Stocks Weaken in Afternoon Trading - InvestorsObserver
Posted: December 17th, 2021, 7:03pm GMT
Sector Update: Health Care Stocks Weaken in Afternoon Trading InvestorsObserver -
Health Care Sector Update for 12/17/2021: NVO,GNFT,IPN.PA,CERN,ORCL,ABEO - Nasdaq
Posted: December 17th, 2021, 7:00pm GMT
-
Sector Update: Health Care Stocks Mixed in Friday Trading - InvestorsObserver
Posted: December 17th, 2021, 4:39pm GMT
Sector Update: Health Care Stocks Mixed in Friday Trading InvestorsObserver -
CHMP rejects Biogen's application for European approval of Aduhelm in Alzheimer's - BioWorld Online
Posted: December 17th, 2021, 4:00pm GMT
-
Primary hepatocellular carcinoma patients post-progression | OTT - Dove Medical Press
Posted: December 17th, 2021, 11:36am GMT
Primary hepatocellular carcinoma patients post-progression | OTT Dove Medical Press -
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma - KPVI News 6
Posted: December 17th, 2021, 10:00am GMT
-
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma - PRNewswire
Posted: December 17th, 2021, 10:00am GMT
-
On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset - BioSpace
Posted: December 17th, 2021, 9:33am GMT
-
Global Nasal Antihistamines Market Trends Analysis & Opportunity Assessment 2021-2031 with a Competition - Benzinga
Posted: December 17th, 2021, 9:15am GMT
-
On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset - GlobeNewswire
Posted: December 17th, 2021, 4:15am GMT
-
Anheart Therapeutics raises $61M in series B for precision oncology pipeline - BioWorld Online
Posted: December 16th, 2021, 8:53pm GMT
-
16 cancer drugs approved in 2021 - Becker's Hospital Review
Posted: December 16th, 2021, 5:39pm GMT
16 cancer drugs approved in 2021 Becker's Hospital Review -
Obituary: Catherine Ann Jones - Portland Press Herald - pressherald.com
Posted: December 16th, 2021, 4:01am GMT
Obituary: Catherine Ann Jones - Portland Press Herald pressherald.com -
Research at Stephenson Cancer Center helps rescue Oklahoma man from cancer - KOCO Oklahoma City
Posted: December 9th, 2021, 6:00am GMT
Research at Stephenson Cancer Center helps rescue Oklahoma man from cancer KOCO Oklahoma City -
15th Anniversary of Cholangiocarcinoma Foundation Commemorated for #GivingTuesday With a $50,000 Match From a Donor - Curetoday.com
Posted: November 24th, 2021, 6:00am GMT
-
Troy musician’s passing sparks more music in his memory - NEWS10 ABC
Posted: November 16th, 2021, 6:00am GMT
-
Diagnosing Cholangiocarcinoma: Challenges and Molecular Profiling - Targeted Oncology
Posted: November 15th, 2021, 6:00am GMT
Diagnosing Cholangiocarcinoma: Challenges and Molecular Profiling Targeted Oncology -
First-Line Durvalumab/Chemotherapy Combo Results in Meaningful Survival Benefit in Advanced Biliary Tract Cancer - Cancer Network
Posted: October 26th, 2021, 5:00am GMT
-
Building on Prior Research, Wilmot Makes Progress on Vexing Liver Cancer - URMC
Posted: September 13th, 2021, 5:00am GMT
-
Prolonged Survival Shown With SIRT and Y90 Plus Chemotherapy in Intrahepatic Cholangiocarcinoma - Targeted Oncology
Posted: September 5th, 2021, 5:00am GMT
-
How Infigratinib Was Evaluated by the FDA to Expedite Approval Process for Treatment of Cholangiocarcinoma - Pharmacy Times
Posted: July 7th, 2021, 5:00am GMT
-
Efficacy of Infigratinib for Treatment of Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma - Pharmacy Times
Posted: July 1st, 2021, 5:00am GMT
-
Global Cholangiocarcinoma Market to Surpass US$ 429.6 Million by 2028, Says Coherent Market Insights (CMI) - Business Wire
Posted: May 7th, 2021, 5:00am GMT
-
Poster Roundup: Boosting Checkpoint Inhibitors, Resistant Mechanisms in Cholangiocarcinoma - AJMC.com Managed Markets Network
Posted: April 4th, 2021, 5:00am GMT
Poster Roundup: Boosting Checkpoint Inhibitors, Resistant Mechanisms in Cholangiocarcinoma AJMC.com Managed Markets Network -
FDA Grants Priority Review to Infigratinib for the Treatment of Cholangiocarcinoma - Targeted Oncology
Posted: December 1st, 2020, 6:00am GMT
-
Promising Data Follow on First Targeted Therapy Approval in Biliary Tract Cancer - Targeted Oncology
Posted: July 27th, 2020, 5:00am GMT